Prolia (denosumab) is a medication for osteoporosis. A healthcare professional administers Prolia via injection under the skin every 6 months. Medicare covers Prolia for beneficiaries. Since a ...

Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products. Wyost and ...

Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.

The Food and Drug Administration has approved Teva's Prolia biosimilar, and the agency is reviewing Teva's Xolair biosimilar application. “The FDA approval of Ponlimsi is a significant milestone that ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week, ...

Biocon receives Health Canada's compliance notice for biosimilars Bosaya and Vevzuo, enhancing treatment options for ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...

Health Canada has granted Biocon a Notice of Compliance for its denosumab biosimilars Bosaya and Vevzuo, referencing Prolia ...